HLS 13RS-142 ORIGINAL

Regular Session, 2013

HOUSE BILL NO. 15

1

BY REPRESENTATIVE MACK

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

CONTROLLED SUBSTANCES: Adds certain compounds to the Schedule I classification of controlled dangerous substances

AN ACT

2	To amend and reenact R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) and to enact R.S.
3	40:961(26.1), relative to controlled dangerous substances; to provide with respect to
4	certain chemical groups within the cathinone Schedule I stimulants; to add
5	substances to the listing of synthetic cannabinoids in Schedule I; to provide for
6	definitions; to provide for certain exceptions; and to provide for related matters.
7	Be it enacted by the Legislature of Louisiana:
8	Section 1. R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) are hereby amended and
9	reenacted and R.S. 40:961(26.1) is hereby enacted to read as follows:
10	§961. Definitions
11	As used in this Part, the following terms shall have the meaning ascribed to
12	them in this Section unless the context clearly indicates otherwise:
13	* * *
14	(26.1) "Nitrogen-heterocyclic analog" means a nitrogen-heterocyclic analog
15	of a synthetic cannabinoid which has a single carbon atom in a cyclic structure of a
16	compound replaced by a nitrogen atom.
17	* * *

§964. Composition of schedules

Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S. 40:962, consist of the following drugs or other substances, by whatever official name, common or usual name, chemical name, or brand name designated:

SCHEDULE I

6 * * *

E. Stimulants. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Federal Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system including its salts, isomers, esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible within the specific chemical designation:

* * *

- (9) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the following ways:
- (i) By substitution in the phenyl ring to any extent with alkyl, <u>hydroxyl</u> alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents.
 - (ii) By substitution at the 3-position with an alkyl substituent.
- (iii) By substitution at the <u>2-amino</u> nitrogen atom with alkyl, dialkyl, or benzyl groups, <u>or methoxybenzyl groups</u>, or by inclusion of the <u>2-amino</u> nitrogen atom in a cyclic structure.
- F. Synthetic cannabinoids. Unless specifically excepted, <u>or contained within</u> a <u>pharmaceutical product approved by the United States Food and Drug Administration</u>, or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of a synthetic cannabinoid found to be in any of the following chemical groups, or any of those groups which

1	contain any synthetic cannabinoid salts, isomers, or salts of isomers, or nitrogen-
2	heterocyclic analogs, whenever the existence of such salts, isomers, or salts of
3	isomers, or nitrogen-heterocyclic analogs is possible within the specific chemical
4	designation, including all synthetic cannabinoid chemical analogues in such groups:
5	(1) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole
6	structure, whether or not substituted in the indole ring to any extent or the naphthyl
7	ring to any extent.
8	(2) Naphthylmethylindoles: any compound containing a 1-H-indol-3-yl-(1-
9	naphthyl)methane structure, whether or not substituted in the indole ring to any
10	extent or the naphthyl ring to any extent.
11	(3) Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole
12	structure, whether or not substituted in the pyrrole ring to any extent or the naphthyl
13	ring to any extent.
14	(4) Naphthylmethylindenes: any compound containing a 1-(1-
15	naphthylmethyl)indene structure, whether or not substituted in the indene ring to any
16	extent or the naphthyl ring to any extent.
17	(5) Phenylacetylindoles: any compound containing a 3-phenylacetylindole
18	structure, whether or not substituted in the indole ring to any extent or the phenyl
19	ring to any extent.
20	(6) Cyclohexylphenols: any compound containing a 2-(3-
21	hydroxycyclohexyl)phenol structure, whether or not substituted in the cyclohexyl
22	ring to any extent or the phenyl ring to any extent.
23	(7) Dibenzopyrans whether or not substituted in the cyclohexyl ring to any
24	extent or the phenyl ring to any extent.
25	(8)(7) Benzoylindoles: any compound containing a 3-(benzoyl)indole
26	structure, whether or not substituted in the indole ring to any extent or the phenyl
27	ring to any extent.

1	(9)(8) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone
2	Tetrahydrodibenzopyrans whether or not substituted in the tricyclic ring system
3	except where contained in cannabis or cannabis resin.
4	(10) (9) (1-(5-fluoropentyl)indol-3-yl)
5	-(2,2,3,3-tetramethylcyclopropyl)methanone Hexahydrodibenzopyrans whether or
6	not substituted in the tricyclic ring system except where contained in cannabis or
7	cannabis resin.
8	(10) Cyclopropanoylindoles: any compound containing a 3-
9	(cyclopropanoyl)indole structure, whether or not substituted in the indole ring to any
10	extent or the cyclopropyl ring to any extent.
11	(11) Adamantoylindoles: any compound containing a 3-(1-
12	adamantoyl)indole structure, whether or not further substituted in the indole ring to
13	any extent or whether or not substituted in the adamantyl ring to any extent.
14	(12) Naphthylamidoindoles: any compound containing a
15	N-(naphthyl)-indole-3-carboxamide structure, whether or not further substituted in
16	the indole ring to any extent or whether or not substituted in the naphthyl ring to any
17	extent.
18	(13) Quinolinylindolecarboxylates: any compound containing a
19	quinolin-8-yl-1H-indole-3-carboxylate structure, whether or not substituted in the
20	indole ring to any extent or the quinloline ring to any extent.
21	* * *

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

Mack HB No. 15

Abstract: Adds certain compounds to the Schedule I classification of controlled dangerous substances.

<u>Present law</u> provides for the classification of controlled dangerous substances in Schedules I through V.

CODING: Words in struck through type are deletions from existing law; words <u>underscored</u> are additions.

HLS 13RS-142 ORIGINAL HB NO. 15

 $\frac{Proposed\ law}{cathinones\ and\ adds\ additional\ substances\ to\ the\ Schedule\ I\ listing\ of\ synthetic\ cannabinoids.}$

Proposed law provides a definition of "nitrogen-heterocyclic analog".

(Amends R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F); Adds R.S. 40:961(26.1))